01597nas a2200325   4500000000100000008004100001260001600042653001400058653001500072653003500087653001400122653001100136653001900147653001200166653002800178653001500206653002500221653003700246653003200283100001200315700001200327700001200339700001400351700001400365245010700379300000900486490000800495520075400503022001401257       2007                            d  c2007 May 1510aApoptosis10aCell Death10aCysteine Proteinase Inhibitors10aCytokines10aHumans10aInterleukin-1010aleprosy10aLeukocytes, Mononuclear10aLeupeptins10aMycobacterium leprae10aProteasome Endopeptidase Complex10aTumor Necrosis Factor-alpha1 aFulco T1 aLopes U1 aSarno E1 aSampaio E1 aSaliba AM00aThe proteasome function is required for Mycobacterium leprae-induced apoptosis and cytokine secretion.  a82-50 v1103 a<p>Previous studies have demonstrated the importance of the ubiquitin-proteasome pathway in the immune response to bacterial pathogens. To investigate the role of this system in the context of leprosy, Mycobacterium leprae-stimulated peripheral blood mononuclear cells (PBMC) were treated with the proteasome inhibitor MG132 to assess the levels of apoptosis and cytokine secretion. The results showed that the inhibition of proteasome activity significantly reduced M. leprae-mediated cell death. In addition, MG132 treatment led to a significant decrease in M. leprae-induced TNF-alpha and IL-10 secretion. Together, these results suggest that modulations of the ubiquitin-proteasome pathway may participate in the human response to M. leprae.</p>  a0165-2478